azacitidine has been researched along with Nausea in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (35.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Afanasyev, B; Beach, CL; Beltrami, G; Borin, L; Botelho de Sousa, A; Čermák, J; Döhner, H; Dombret, H; Dong, Q; Frairia, C; Giai, V; Jang, JH; Kizil Çakar, M; Kumar, K; La Torre, I; Montesinos, P; Ofran, Y; Ossenkoppele, GJ; Pocock, C; Porkka, K; Ravandi, F; Roboz, GJ; Rybka, J; Sandhu, I; Sayar, H; Selleslag, D; Skikne, B; Turgut, M; Wei, AH | 1 |
| Ahuja, N; Anders, NM; Azad, N; Downs, M; Durham, JN; Gaillard, SL; Reiss, KA; Rudek, MA; Sartorius-Mergenthaler, S; Sharma, A; Zahurak, M | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Breed, C; Latsko, JM; Shadduck, RK; Stone, R | 1 |
| Creagan, ET; Hartmann, LC; Loprinzi, CL; Schaid, DJ | 1 |
| Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ | 1 |
| Muggia, FM; Slavik, M; Von Hoff, DD | 1 |
| Keller, JW; Miller, DS; Vogler, WR | 1 |
| Arkun, SN; Bartolucci, AA; Vélez-Garcia, E; Vogler, WR | 1 |
| Baehner, RL; Berkow, RL; Weetman, RM; Weisman, SJ | 1 |
| Hahn, RG; Moertel, CG; Reitemeier, RJ; Schutt, AJ | 1 |
| Finklestein, JZ; Karon, M; Leimbrock, S; Nesbit, ME; Sieger, L; Swaney, JJ | 1 |
2 review(s) available for azacitidine and Nausea
| Article | Year |
|---|---|
New antineoplastic drugs and their proper use.
Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting | 1976 |
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
Topics: Animals; Azacitidine; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; Europe; Female; Humans; Kinetics; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Liver; Nausea; Neoplasms, Experimental; Neuromuscular Diseases; RNA, Messenger; United States; Vomiting | 1976 |
14 trial(s) available for azacitidine and Nausea
| Article | Year |
|---|---|
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Survival Analysis | 2020 |
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Depsipeptides; DNA Modification Methylases; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Long Interspersed Nucleotide Elements; Male; Maximum Tolerated Dose; Methyltransferases; Middle Aged; Nausea; Neoplasms | 2019 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2012 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Chest Pain; Female; Humans; Immunologic Factors; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nausea; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Vomiting | 1993 |
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
Topics: Azacitidine; Clinical Trials as Topic; Drug Evaluation; Granulocytes; Humans; Infusions, Parenteral; Leukopenia; Nausea; Neoplasm Metastasis | 1977 |
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Azacitidine; Blood Cell Count; Blood Platelets; Clinical Trials as Topic; Cytidine; Female; Gastrointestinal Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Nausea; Triazines; Vomiting | 1972 |
5-Azacytidine: a new active agent for the treatment of acute leukemia.
Topics: Adolescent; Azacitidine; Bone Marrow Examination; Child; Child, Preschool; Chlorpromazine; Clinical Trials as Topic; Cytidine; Digestive System; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nausea; Remission, Spontaneous; Triazines | 1973 |
4 other study(ies) available for azacitidine and Nausea
| Article | Year |
|---|---|
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
MDS: practical treatment approaches for physicians and nurses.
Topics: Azacitidine; Bone Marrow Transplantation; Decision Trees; DNA Methylation; Drug Administration Schedule; Hematopoietic Cell Growth Factors; Humans; Injections, Subcutaneous; Medical Oncology; Myelodysplastic Syndromes; Nausea; Oncology Nursing | 2005 |
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
Topics: Agranulocytosis; Azacitidine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nausea; Neoplasm Metastasis; Vomiting | 1976 |
5-Azacytidine: acute central nervous system toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Central Nervous System; Child; Humans; Leukemia, Monocytic, Acute; Male; Nausea; Vomiting | 1985 |